Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31
Phase 41

Trial Status

Completed1
Terminated1

Role Distribution

Principal Investigator1
Other Roles1
PI Rate50%

Activity Timeline

Clinical Trials (2)

NCT03040427Phase 4Terminated
The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
Cardiac Amyloidosis
StudychairStart date: 2017-01-01
NCT02104817Phase 3Completed
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
PrincipalinvestigatorStart date: 2014-10-30

Research Network

Collaboration Network

4 collaborators·4 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT03040427Phase 4StudyChair

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Cardiac Amyloidosis
Terminated
NCT02104817Phase 3PrincipalInvestigator

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Completed

All 2 trials loaded